{"eventGroups":[{"description":"Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.\n\nrosiglitazone maleate : Given orally","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Group 1 (ACTH-secreting Adenomas)"},{"description":"Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.\n\nrosiglitazone maleate : Given orally","id":"EG001","otherNumAffected":0,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"Group 2 (Non-secreting Macroadenomas)"}],"frequencyThreshold":"5"}